Copyright
©2010 Baishideng.
World J Diabetes. Mar 15, 2010; 1(1): 3-7
Published online Mar 15, 2010. doi: 10.4239/wjd.v1.i1.3
Published online Mar 15, 2010. doi: 10.4239/wjd.v1.i1.3
Table 2 In vitro enzymatic inhibition activity of the marketed PDE5-i (IC50 nmol/L)
| PDE isoform | Sildenafil | Tadalafil | Vardenafil |
| PDE-1 | 60 | > 10 000 | 257 |
| PDE-2 | > 10 000 | > 10 000 | > 10 000 |
| PDE-3 | 2 600 | > 10 000 | 3 600 |
| PDE-4 | 1 800 | > 10 000 | 5 700 |
| PDE-5 | 3.8 | 1 | 0.7 |
| PDE-6 | 7.4 | 780 | 15.7 |
- Citation: Aversa A. Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes 2010; 1(1): 3-7
- URL: https://www.wjgnet.com/1948-9358/full/v1/i1/3.htm
- DOI: https://dx.doi.org/10.4239/wjd.v1.i1.3